Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun 18;149(25):2026-2028.
doi: 10.1161/CIRCULATIONAHA.124.069479. Epub 2024 Jun 17.

Effects of Dapagliflozin on Body Composition and Its Relation to Hemodynamics in Heart Failure With Preserved Ejection Fraction

Jwan A Naser  1 , Atsushi Tada  1 , Tomonari Harada  1 , Yogesh N V Reddy  1 , Rickey E Carter  2 , Jeffrey M Testani  3 , Michael D Jensen  4 , Barry A Borlaug  1
Affiliations

Effects of Dapagliflozin on Body Composition and Its Relation to Hemodynamics in Heart Failure With Preserved Ejection Fraction

Jwan A Naser et al. Circulation. .
No abstract available

Keywords: adiposity; dapagliflozin; heart failure, diastolic; intra-abdominal fat; pulmonary wedge pressure.

PubMed Disclaimer

Conflict of interest statement

Disclosures Dr Borlaug receives research support from the National Institutes of Health (NIH) and the US Department of Defense, and research grant funding from AstraZeneca, Axon, GlaxoSmithKline, Medtronic, Mesoblast, Novo Nordisk, Rivus, and Tenax Therapeutics, as well. He has served as a consultant for Actelion, Amgen, Aria, Axon Therapies, BD, Boehringer Ingelheim, Cytokinetics, Edwards Lifesciences, Eli Lilly, Imbria, Janssen, Merck, Novo Nordisk, NGM, NXT, and VADovations, and is named inventor (US Patent No. 10,307,179) for the tools and approach for a minimally invasive pericardial modification procedure to treat heart failure.

Figures

Figure
Figure. Effects of dapagliflozin on body composition and its relation to hemodynamics in heart failure with preserved ejection fraction.
[A] Proportional distribution of body weight reduction by fat, fat-free mass, plasma volume, and bone mineral content-to-total mass lost in the dapagliflozin group. The lean tissue proportion is presented after subtracting contribution of plasma volume, which is part of lean tissue. [B] Relative change in fat mass in the dapagliflozin and placebo arms over 24 weeks. The bars represent mean values and whiskers represent the mean standard error. [C] Correlation between changes in trunk fat and changes in pulmonary capillary wedge pressure (PCWP). [D] Correlations between changes in fat free mass and plasma volume.
See this image and copyright information in PMC

References

    1. Borlaug BA, Jensen MD, Kitzman DW, Lam CSP, Obokata M, Rider OJ. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res. 2023;118:3434–3450. doi: 10.1093/cvr/cvac120 - DOI - PMC - PubMed
    1. Kosiborod MN, Abildstrom SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, Hovingh GK, Kitzman DW, Lindegaard ML, Moller DV, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023;389:1069–1084. doi: 10.1056/NEJMoa2306963 - DOI - PubMed
    1. Borlaug BA, Kitzman DW, Davies MJ, Rasmussen S, Barros E, Butler J, Einfeldt MN, Hovingh GK, Moller DV, Petrie MC, et al. Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial. Nat Med. 2023;29:2358–2365. doi: 10.1038/s41591-023-02526-x - DOI - PMC - PubMed
    1. Vaduganathan M, Docherty KF, Claggett BL, Jhund PS, de Boer RA, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022;400(10354):757–767. doi: 10.1016/S0140-6736(22)01429-5 - DOI - PubMed
    1. Borlaug BA, Reddy YNV, Braun A, Sorimachi H, Omar M, Popovic D, Alogna A, Jensen MD, Carter R. Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction: The CAMEO-DAPA Trial. Circulation. 2023;148:834–844. doi: 10.1161/CIRCULATIONAHA.123.065134 - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources